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Cystic fibrosis-related liver disease affects approximately one third of all patients with cystic fibrosis. Initial signs of other liver diseases
including the genetically determined disorders of the liver co-inherited with cystic fibrosis may be obscured by or ascribed to cystic fibrosis-
related liver disease. We report a patient shown to suffer simultaneously from cystic fibrosis and hepatic Wilson disease. Our case documents that
in patients with cystic fibrosis presenting with liver disease, when unusual clinical and/or laboratory abnormalities appear and fail to respond to
standard therapy, a second disease, including rare inherited metabolic disorders such as the hepatic form of Wilson disease or α1-antitrypsin
deficiency, should be suspected.
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Cystic fibrosis-related liver disease (CFLD) affects approxi-
mately one third of all patients with cystic fibrosis (CF, OMIM
#219700), most severely as focal or multilobular liver cirrhosis
associated with steatosis [1,2]. Cirrhosis is related to increased
viscosity of bile and to injury or necrosis of biliary epithelia,
arising from decreased function and/or aberrant expression of
CFTR. That only some patients with CF develop CFLD,
which varies greatly in severity even among patients with the
same CFTR genotype, indicates that other factors influence its
pathogenesis. Exogenous factors, concomitant events, and
genetic modifiers for CFLD are listed elsewhere [1]. Initial
signs of other liver diseases including the genetically deter-
mined disorders of the liver co-inherited with CF may be
obscured by or ascribed to CFLD. Here we report, to our best
knowledge, the first patient shown to suffer simultaneously
from both CF and Wilson disease (WD; OMIM #277900), a⁎ Corresponding author. Tel.: +420 2 2443 2001; fax: +420 2 2443 2020.
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doi:10.1016/j.jcf.2008.09.003rare autosomal-recessive disorder characterized by hepatic
accumulation of intracellular copper resulting in progressive
liver disease, and neurological abnormalities.
2. Case report
The patient, of Caucasian origin (Czech), was born to
healthy non-consanguineous parents at 31 weeks of gestation.
He suffered from meconium ileus which was treated with
temporary ileostomy. CF was suspected. The mean sweat
chloride concentration was 98 mmol/L. Homozygosity for the
prevalent mutation F508del was found by screening of CFTR
(Fig. 1A). Sino-pulmonary and pancreatic disease developed
during the first year of life. Liver disease (LD), considered to be
CFLD, was first manifest at age 5 years, after appendectomy, as
elevation of serum liver enzyme activities (Table 1) with
hepatomegaly and mildly increased hepatic echogenicity on
ultrasound examination. As no signs of hemolysis were present,
mild unconjugated hyperbilirubinemia was ascribed to Gilbert
syndrome (OMIM #143500), confirmed by genotyping of the
UGT1A1 promoter (Fig. 1B). Ursodeoxycholic acid was startedd by Elsevier B.V. All rights reserved.
Fig. 1. Mutations in CFTR, UGT1A1, and ATP7B. Homozygous mutations F508del in CFTR (A) and A(TA)7TAA in the UGT1A1 promoter (B) were found by
fragment analysis. The homozygous variant −3279TNC in the UGT1A1 promoter was detected as a PCR-Hpy8I restriction-enzyme fragment length polymorphism
(B). The heterozygous mutation c.2930CNT in ATP7B was detected by gene sequencing (C) and as a PCR-NlaIII restriction-enzyme fragment length polymorphism
(not shown). WT — wildtype, (TA)7 — A(TA)7TAA.
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(Table 1) but began again to rise at age 7 years despite
continuous administration of ursodeoxycholic acid.
At age 9 years the patient was hospitalized with anorexia and
markedly abnormal alanine aminotransferase (ALT), aspartate
aminotransferase (AST) and gamma–glutamyl transferase
(GGT) values (Table 1). Height was within 0.1 SD of normal
range and body mass index was 14.4 (−1 SD). Hepatomegaly,
splenomegaly and signs of portal hypertension were not found.
Values for albumin, cholesterol, plasma cholinesterase, α-
fetoprotein, α1-antitrypsin, prothrombin time and immunoglo-
bulins were within the normal range. Autoantibodies (ANA,
ANCA, ASMA, LKM, AMA, dsDNA, ENA and SLA) wereTable 1
Laboratory findings
Marker 5 years 9 years 11 years Ref. range
Total bilirubin (µmol/L) 20 12 43 2–17
Direct bilirubin (µmol/L) b1 b1 13 b5
ALT (µkat/L) 2.2, 1.6a 3.9 0.9 0.25–0.6
AST (µkat/L) 0.7, 0.7a 3.3 0.5 0.2–0.63
ALP (µkat/L) 6.2, 4.9a 7.1 9.7 1.1–7.5
GGT (µkat/L) 0.6, 0.4a 1.0 0.1 0.1–0.4
Albumin (g/L) 39 51 42 35–53
Cholesterol (mmol/L) 3.9 3.6 3.2 2.6–4.8
Prothrombin time (INR) – 0.95 0.97 0.8–1.2
Serum copper (µmol/L) – 4.1 2.4 10–21
Ceruloplasmin (g/L) – 0.05 0.05 0.18–0.45
Urinary copper output (µg/24 h) – 63 508b 15–40
INR— international normalized ratio.
avalues before and after 3 months of treatment with ursodeoxycholic acid.
bvalue during treatment with D-penicillamine.not detected. Serologic evidence for hepatotropic-virus infec-
tion (HAV, HBV, HCV, EBV, CMV and HSV) was not found.
The gallbladder and extrahepatic bile ducts were sonographi-
cally normal and without gallstones.
Serum values for copper and ceruloplasmin were repeatedly
far below the normal range (Table 1). Urinary output of copper
was marginally elevated and rose to 1422 µg/24 h with formal
D-penicillamine challenge according to Roberts and Schilsky
[3] (500 mg of D-penicillamine at the beginning and again
12 h later during 24-hour urine collection, evidence for
WD N1600 µg/24 h). Kayser–Fleischer rings were not present.
Findings on neurologic examination were normal. Quantitative
analysis of copper in a liver biopsy specimen (1450 µg/g dry
weight, normalb50 µg/g) confirmed hepatic WD. The liver
biopsy specimen was too small for both copper quantification
and histologic study.
Molecular genetic analysis of all exons of ATP7B together
with their adjacent intronic regions disclosed the known
missense mutation c.2930CNT (p.T977M) in exon 13 [4]
(Fig. 1C), confirmed present in the mother as well. However, a
second mutated allele in trans was not found on sequencing of
both patients' DNA strands. Complex intragenic rearrange-
ments were not detected by multiplex ligation-dependent probe
amplification (MRC-Holland™, Amsterdam, The Netherlands).
D-penicillamine and pyridoxine were begun. Clinical-
biochemistry abnormalities resolved gradually, reaching
almost normal values after 18 months of treatment. Thirty
months after initiation of D-penicillamine therapy, body mass
index had increased to 17.2 (−0.4 SD), urinary copper
excretion dropped to 508 µg/24 h while receiving D-
penicillamine at maintenance dose and clinical-biochemistry
indices of hepatobiliary injury remained normal, except for
bilirubin and ALT values (Table 1).
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The primary aim of clinical and laboratory screening for
CFLD is early diagnosis during an asymptomatic phase.
Screening is particularly important in patients at increased
risk of CFLD conferred by male sex, meconium ileus, and
pancreatic insufficiency, as well as by the “severe” pancreatic
CFTR genotype with Class I–III alleles in homozygous or
compound heterozygous state. In our patient, mild clinical-
biochemistry abnormalities led to the diagnosis of CFLD,
supported by improvement in laboratory parameters within
3 months after ursodeoxycholic acid therapy began. Unex-
pected recurrence of laboratory signs of hepatobiliary disease
suggested an intercurrent event and/or a co-inherited genetic
disease. The final diagnosis of simultaneously present WD was
supported by decreased serum ceruloplasmin concentrations,
urinary copper excretion with formal penicillamine challenge
exceeding 5× the upper limit of normal value [5], increased
hepatic copper concentration, presence of a mutation in ATP7B
and a clinical response to D-penicillamine treatment. The result
of penicillamine challenge test interpreted using the cutoff limit
of 1600 µg/24 h [3] was marginal, however, still compatible
with WD [6].
As WD is an autosomal-recessive disorder, heterozygotes
with a single ATP7B mutation should be unaffected. Molecular
genetic investigation performed in our patient revealed only one
pathogenic ATP7B allele: although the detected c.2930CNT
ATP7B mutation is rare in Czech patients [7], it is the second
most common mutated ATP7B allele in Sweden [4] and its
pathogenic potential is undisputable. A single ATP7B gene
mutation, or none, was found in 27.5% of 200 unrelated WD
patients of Czech or Slovak origin reported by Vrábelová et al.
[7]. Therefore we cannot definitively state that another mutation
in trans is not located within promoter or intronic sequences of
ATP7B that were not examined. Nonetheless, we believe that
WD in our patient most likely resulted from compound
heterozygosity at ATP7B, since the mother transmitting mutated
alleles of both ATP7B and CFTR genes is asymptomatic and
her serum levels of copper and ceruloplasmin and urinary
output of copper were normal.
The contribution of CF to LD was scant at worst in our
patient. The child has never been severely cholestatic, no
abnormalities of bile ducts were found by repeated ultrasono-
graphy and the copper content of liver tissue was within the
range typical for paediatric WD. This does not mean, however,
that cholestasis or chronic liver injury caused by CF cannotpromote manifestation or worsen the course of simultaneously
present WD. Early diagnosis of WD is of particular importance
because acute liver failure can be prevented by specific therapy.
We conclude that in patients with CF presenting with LD,
when unusual clinical and/or laboratory abnormalities appear
and fail to respond to standard therapy, a second disease,
including rare inherited metabolic disorders such as α1-
antitrypsin deficiency [8] or the hepatic form of WD (this
observation), should be suspected.
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